Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lesinurad plus xanthine oxidase inhibitor in gout with moderate renal impairment
2017-001191-30Phase 4Terminated
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gout comparing Lesinurad + xanthine oxidase inhibitor with Placebo + xanthine oxidase inhibitor (2 arms). Primary endpoint: Safety endpoints. Started Aug 2017; status: terminated.
02
Drugs
lesinurad
03
Conditions
gout
Beyond the preview
Go deeper on 2017-001191-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001191-30.